Edition:
United Kingdom

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

2.97USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$2.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
83,823
52-wk High
$40.20
52-wk Low
$2.89

Chart for

About

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally... (more)

Overall

Beta: 3.04
Market Cap(Mil.): $39.03
Shares Outstanding(Mil.): 30.25
Dividend: --
Yield (%): --

Financials

  BIOC.OQ Industry Sector
P/E (TTM): -- 32.30 32.76
EPS (TTM): -1.26 -- --
ROI: -328.01 13.94 14.61
ROE: -550.52 16.79 16.33

BRIEF-Biocept Inc Files For Mixed Shelf Of Up To $50 Million

* BIOCEPT INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING Source http://bit.ly/2wJv6pr Further company coverage:

15 May 2018

BRIEF-Biocept Inc Obtains Patent For A Certain Technology In China

* BIOCEPT OBTAINS PATENT FOR ITS TARGET SELECTOR MOLECULAR BIOMARKER TECHNOLOGY IN CHINA Source text for Eikon: Further company coverage:

29 Mar 2018

BRIEF-Biocept Reports Q4 Loss Of $0.18 Per Share

* BIOCEPT REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

28 Mar 2018

BRIEF-Biocept And Thermo Fisher Scientific Enter Into Technology And Commercial Collaboration

* BIOCEPT AND THERMO FISHER SCIENTIFIC ENTER INTO TECHNOLOGY AND COMMERCIAL COLLABORATION

28 Mar 2018

Earnings vs. Estimates